ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

By afschroeder • February 12, 2026

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S. ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL. Blood Adv. 2026 Feb 11:bloodadvances.2021006479. doi: 10.1182/bloodadvances.2021006479. Epub ahead of print. PMID: 41670624.

Tags: Hematology/Oncology, Publications

Related Posts

Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Oluwole OO, Ghobadi A, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Baer MR, Schiller[...]

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]